Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2012 /
Vandetanib increases progression free survival in medullary thyroid carcinoma

28th - 29th Jun 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.07.12
Views: 4726
Rating:

Dr Nick Botwood - AstraZeneca, UK

Dr Nick Botwood talks to ecancer.tv about results demonstrating the efficacy of vandetanib in the treatment of medullary thyroid carcinoma. Vandetanib was originally developed for the treatment of non-small cell lung cancer; however, clinical trials did not demonstrate sufficient benefit for it to be approved.

However, further trials established that this agent is active against the RET oncogene and subsequently AstraZeneca started trials assessing the use vandetanib in patients with medullary thyroid carcinoma.

A Phase III trial was comparing vandetanib with no therapy and vandetanib with standard therapy showed significant improvement in drug response rate and significant increases in patient progression free survival. As a result, vandetanib has been approved for use in USA, Canada and Europe for patients with advanced aggressive or progressive medullary thyroid carcinoma, or patients with symptoms from their disease.

Dr Botwood concludes by discussing the movement towards genetically targeted cancer therapies and talks about the need for further collaborations between academia and pharmaceutical companies.

Filming Supported by Amgen

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation